. Akorn (WKN: 888920)AKRX

Kurzporträt



Logo Akorn, Inc.
Manufactures and distributes therapeutic, diagnostic and surgical pharmaceuticals

Akorn, Inc. manufactures and markets a full line of diagnostic and therapeutic ophthalmic pharmaceuticals as well as niche hospital drugs and injectable pharmaceuticals.

It also markets and distributes vaccines purchased from outside sources.

The company customers include physicians, optometrists, hospitals, wholesalers, group purchasing organizations, retail pharmacy chains and other pharmaceutical companies.

It operates through three segments: Ophthalmic, Hospital Drugs & Injectables and Contract Services.

The Ophthalmic segment market a full line of diagnostic and therapeutic ophthalmic pharmaceutical products.

The diagnostic products, primarily used in the office setting include mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, angiography dyes and others.

The therapeutic products, sold primarily to wholesalers, chain drug stores and other national account customers include antibiotics, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines and anti-edema medications.

The non-pharmaceutical products include various artificial tear solutions, preservative-free lubricating ointments and eyelid cleansers.

The Hospital Drugs & Injectables segment markets a line of niche hospital drug and injectable pharmaceutical products, including antidotes, anti-infectives, controlled substances for pain management and anesthesia, and other selected pharmaceutical products.

These products are predominately sold to hospitals through the wholesale distribution channel.

The Contract Services segment manufactures ophthalmic and injectable pharmaceutical products for third party pharmaceutical customers based on their specifications.

The company was founded in 1971 and is headquartered in Lake Forest, IL.
Mitarbeiteranzahl : 1 665 Personen.  
http://de.4-traders.com/AKORN-INC-42504/fundamentals/

http://investors.akorn.com/phoenix.zhtml?c=78132&p=irol-irhome  

http://seekingalpha.com/article/3644536-akorns-current-price-is-nuts
 

http://www.finanznachrichten.de/suche/...suche=akrx&redirect=true

Earnings Guidance Affirmed for Full Year 2016

The Company is maintaining its full year 2016 financial guidance inclusive of net revenue of $1,060 - $1,080 million, GAAP diluted earnings per share of $1.56 - $1.66, and adjusted diluted earnings per share (non-GAAP) of $2.10 - $2.20.

da sollte bis Jahresmitte ein Bio aus USA laufen,........

oder übernommen werden  

http://www.marketbeat.com/stocks/NASDAQ/AKRX/...ocialMedia-StockTwits  

​

 

http://finance.yahoo.com/news/...es-first-quarter-2016-204301907.html  

 

Akorn Receives FDA Approval for Ephedrine Sulfate Injection, USP

http://www.4-traders.com/AKORN-INC-42504/news/...ection-USP-23972906/  

http://www.t-online.de/finanzen/boerse/news/...s-durch-fresenius.html  

Fresenius sagt Übernahme von Akorn ab

https://boerse.ard.de/aktien/fresenius-will-akorn-nicht100.html

 

http://...-43bn-merger-with-us-generic-drugmaker-akorn-230418-6124570  

https://www.fiercepharma.com/pharma/...-battle-royale-could-come-next  

http://www.spiegel.de/wirtschaft/unternehmen/...ug-vor-a-1205904.html  

Sind noch in der Bodenfindungsphase, allerdings werden die Ausschläge nach unten schon spürbar kleiner (Tagestief 10,76$).  

https://www.finanzen.ch/nachrichten/aktien/...-vor-Gericht-1027343325  

Die Akorn Aktie hat sich seit Mai schonwieder gut erholt. Das zeigt das man solche Abstürze ruhig spekulativ kaufen kann. Vorrausgesetzt man spring nicht gleich rein (#10) sondern wartet geduldig (#14)

https://www.finanznachrichten.de/...-treffen-sich-vor-gericht-015.htm  

Gerichtsverhandlung läuft  

http://www.manager-magazin.de/finanzen/boerse/...-kurs-a-1224701.html  

Fresenius muss Akorn nicht übernehmen

http://www.manager-magazin.de/unternehmen/artikel/...n-a-1231057.html

 

 

 

https://www.fiercepharma.com/pharma/...-rules-fresenius-legally-ended  

So bin gestern zu 5,55$ eingestiegen. Denke da sollte ne Gegenreaktionen kommen . Der  Kursverfall ist doch stark übertrieben.  

Akorn meldet schwache Ergebnisse für Q3/18

http://investors.akorn.com/news-releases/...hird-quarter-2018-results

 

neues 52 Wochen-Tief!
Die Marktteilnehmer scheinen nicht mehr dran zu glauben, dass Akorn noch Chancen hat Fresenius gerichtlich zur Übernahme zu zwingen.